CoChat

Targeting Translation of mRNA as a Therapeutic Strategy in Cancer

Pal, Ipsita, Safari, Maryam, Jovanovic, Marko, Bates, Susan E., Deng, Changchun · 2019 · Current Hematologic Malignancy Reports

The DOI matches its Crossref record; 102 of the 102 references it cites were found in a registry or an index.

Abstract

Purpose of review To highlight recent results in targeting mRNA translation and discuss the results and prospects of translation inhibitors in cancer therapy. Recent findings Until recently, inhibitors of mRNA translation have been thought to likely lack a therapeutic window. In 2012, the Food and Drug Administration (FDA) approved omacetaxine mepesuccinate (homoharringtonine) for the treatment of adults with chronic myelogenous leukemia (CML) who are resistant to at least two tyrosine kinase inhibitors. Since then, a few drugs, notably tomivosertib (eFT-508), selinexor (KPT-330), and ribavirin, have entered clinical trials. These drugs are known to inhibit mRNA translation. More recently, a number of interesting studies report that discrete subsets of proteins in cancer cells may be selectively targeted at the translation step, through inhibiting signals such as phospho-4E-BP1, eIF4A, and eIF4E. Promising therapies using these strategies have demonstrated potent anti-tumor activity in preclinical cancer models. The growing number of translation inhibitors with diverse mechanisms, coupled with emerging insights into translational regulation of different cancer-promoting genes, suggests a bright new horizon for the field of therapeutic targeting of mRNA translation in cancer.

Overview

Integrity signals

Registry

Crossref · 10.1007/s11899-019-00530-y

Cites

102 of 102 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

1 retracted

Show all 102 references

Cited by

See all 46

Metadata

Authors
Pal, I., Safari, M., Jovanovic, M., Bates, S. E., & Deng, C.
Affiliations
Columbia University Irving Medical Center (US)
Corresponding author
Deng, Changchun
Venue
Current Hematologic Malignancy Reports
Published
2019-06-24
Volume
14
Issue
4
Pages
219-227
ISSN
  • 1558-8211 (ISSN-L)
  • 1558-822X
OpenAlex
W2951271467
Cited by
46
References
102
Citations by year
2026: 1 · 2025: 5 · 2024: 1 · 2023: 6 · 2022: 12 · 2021: 13 · 2020: 7 · 2019: 1
FWCI
0.75
Type
journal article
Language
en
Open access
closed
Licence
Locations
  • Current Hematologic Malignancy Reports (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA and protein synthesis mechanisms
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › PI3K/AKT/mTOR signaling in cancer
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer Mechanisms and Therapy
Keywords
mRNA translation inhibition, translation inhibitors, cancer therapy, homoharringtonine, omacetaxine mepesuccinate, chronic myeloid leukemia, selinexor, ribavirin, 4E-BP1, eIF4A, eIF4E, translational regulation, tyrosine kinase inhibitor resistance
MeSH terms
Animals, Antineoplastic Agents, Humans, Neoplasms, RNA, Messenger, Protein Biosynthesis, Signal Transduction, Biomarkers, Gene Expression Regulation, Neoplastic, Molecular Targeted Therapy

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Targeting Translation of mRNA as a Therapeutic Strategy in Cancer. https://app.cochat.ai/papers/10.1007/s11899-019-00530-y
The paper
Pal, I., Safari, M., Jovanovic, M., Bates, S. E., & Deng, C. (2019). Targeting Translation of mRNA as a Therapeutic Strategy in Cancer. Current Hematologic Malignancy Reports. https://doi.org/10.1007/s11899-019-00530-y

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.